Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial (Q33427744)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial |
scientific article |
Statements
1 reference
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial (English)
1 reference
Ignace Vergote
1 reference
Mariusz Bidziński
1 reference
Giovanni Scambia
1 reference
Felix Hilpert
1 reference
Andreas du Bois
1 reference
Gunnar Kristensen
1 reference
Alexander Reuss
1 reference
Nicoletta Colombo
1 reference
Ursula Denison
1 reference
Jose M Del Campo
1 reference
Petronella Ottevanger
1 reference
Martin Heubner
1 reference
Thomas Minarik
1 reference
Emmanuel Sevin
1 reference
Nikolaus de Gregorio
1 reference
Jacobus Pfisterer
1 reference
Susanne Malander
1 reference
Mansoor R Mirza
1 reference
Werner Meier
1 reference
Maria O Nicoletto
1 reference
Line Bjørge
1 reference
Alain Lortholary
1 reference
Martin Oliver Sailer
1 reference
Michael Merger
1 reference
Philipp Harter
1 reference
AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium
1 reference
13 November 2015
1 reference
1 reference
17
1 reference
78-89
1 reference
Identifiers
1 reference
1 reference